| Name | 3-(benzenesulfonyl)-8-piperazin-1-ylquinoline |
|---|---|
| Synonyms |
RVT-101
Intirdine HCl (SB-742457 3-Phenylsulfonyl-8-(piperazin-1-yl)quinoline SB 742457;RVT 101;SB742457;RVT Quinoline,3-(phenylsulfonyl)-8-(1-piperazinyl) 3-(phenylsulfonyl)-8-(piperazin-1-yl)quinoline SB-742457(RVT-101) SB742457 ,S2894 SB 742457/GSK Intirdine, 10 mM in DMSO Intirdine(SB742457) SB 742457/GSK 742457/SB Gsk Sb-742457 //BP 3-(BENZENESULFONYL)-8-(PIPERAZIN-1-YL)QUINOLINE GSK-742457 Quinoline, 3-(phenylsulfonyl)-8-(1-piperazinyl) Intepirdine UNII-2IOB2M82HY SB-742,457 SB742457; SB 742457; SB-742457; RVT-101; RVT 101; RVT101. INTIRDINE Sb-742457 SB742457 (Intirdine), 5-HT6 antagonist Intirdine (SB-742457, RVT-101) SB-742457 RVT101. intirdine SB742457:Intirdine 3-(Phenylsulfonyl)-8-(1-piperazinyl)quinoline |
| Description | SB742457 is a highly selective 5-HT6 receptor antagonist with pKi of 9.63; exhibits >100-fold selectivity over other receptors.IC50 Value: 9.63 (pKi)Target: 5-HT6 ReceptorSB-742457, a 5-HT6 receptor antagonist, which extends into Alzheimer disease (AD) sufferers further highlights the therapeutic promise of this mechanistic approach. Alzheimer's disease is a devastating neurological condition characterized by a progressive decline in cognitive performance accompanied by behavioral and psychological syndromes, such as depression and psychosis. With the subsequent development of selective 5-HT6 receptor antagonists, preclinical studies in rodents and primates have elucidated the function of this receptor subtype in more detail. It is increasingly clear that blockade of 5-HT6 receptors leads to an improvement of cognitive performance in a wide variety of learning and memory paradigms and also results in anxiolytic and antidepressant-like activity. SB-742457 is generally safe and well tolerated and may be efficacious in Alzheimer disease. |
|---|---|
| Related Catalog | |
| References |
[6]. SB-742457 |
| Density | 1.3±0.1 g/cm3 |
|---|---|
| Boiling Point | 608.3±45.0 °C at 760 mmHg |
| Molecular Formula | C19H19N3O2S |
| Molecular Weight | 353.438 |
| Flash Point | 321.7±28.7 °C |
| Exact Mass | 353.119812 |
| PSA | 70.68000 |
| LogP | 2.10 |
| Vapour Pressure | 0.0±1.7 mmHg at 25°C |
| Index of Refraction | 1.649 |
| Storage condition | -20℃ |
|
~73%
607742-69-8 |
| Literature: GLAXO GROUP LIMITED Patent: WO2005/26125 A1, 2005 ; Location in patent: Page/Page column 21-22 ; WO 2005/026125 A1 |
|
~84%
607742-69-8 |
| Literature: GLAXO GROUP LIMITED Patent: WO2007/39238 A1, 2007 ; Location in patent: Page/Page column 14-16 ; |
|
~69%
607742-69-8 |
| Literature: Emmett, Edward J.; Hayter, Barry R.; Willis, Michael C. Angewandte Chemie - International Edition, 2013 , vol. 52, # 48 p. 12679 - 12683 Angew. Chem., 2013 , vol. 125, # 48 p. 12911 - 12915,5 |
|
~%
607742-69-8 |
| Literature: Journal of Medicinal Chemistry, , vol. 57, # 9 p. 3884 - 3890 |
|
~%
607742-69-8 |
| Literature: Journal of Medicinal Chemistry, , vol. 57, # 9 p. 3884 - 3890 |
|
~%
607742-69-8 |
| Literature: Journal of Medicinal Chemistry, , vol. 57, # 9 p. 3884 - 3890 |
|
~%
607742-69-8 |
| Literature: Journal of Medicinal Chemistry, , vol. 57, # 9 p. 3884 - 3890 |